

## Product datasheet for TL314184V

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## Catalase (CAT) Human shRNA Lentiviral Particle (Locus ID 847)

**Product data:** 

**Product Type:** shRNA Lentiviral Particles

Product Name: Catalase (CAT) Human shRNA Lentiviral Particle (Locus ID 847)

Locus ID: 847

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** CAT - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** NM 001752, NM 001752.1, NM 001752.2, NM 001752.3, BC110398, BC110398.1, BC027300,

BC112217, BC112219, NM 001752.4

UniProt ID: P04040

Summary: This gene encodes catalase, a key antioxidant enzyme in the bodies defense against oxidative

stress. Catalase is a heme enzyme that is present in the peroxisome of nearly all aerobic cells. Catalase converts the reactive oxygen species hydrogen peroxide to water and oxygen and thereby mitigates the toxic effects of hydrogen peroxide. Oxidative stress is hypothesized to play a role in the development of many chronic or late-onset diseases such as diabetes, asthma, Alzheimer's disease, systemic lupus erythematosus, rheumatoid arthritis, and cancers. Polymorphisms in this gene have been associated with decreases in catalase activity

RefSeq, Oct 20091

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.

but, to date, acatalasemia is the only disease known to be caused by this gene. [provided by





### Catalase (CAT) Human shRNA Lentiviral Particle (Locus ID 847) – TL314184V

# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).